View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 26 (HealthDay News) -- The U.S. Food and Drug Administration has alerted consumers and health care providers regarding the potential increased risk of hip, wrist and spine fractures associated with high doses or long-term use of proton-pump inhibitors (PPIs).
PPIs are available by prescription as esomeprazole (Nexium), dexlansoprazole (Dexilant), omeprazole (Prilosec, Zegerid), lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (Aciphex), as well as over-the-counter (OTC) as omeprazole (Prilosec OTC, Zegerid OTC) and lansoprazole (Prevacid 24HR).
The labeling for both prescription and OTC PPIs will be updated to address this increased risk. The FDA's decision to revise the labeling of these drugs was based on epidemiologic studies showing an increased risk of fracture of the hip, wrist and spine in patients using PPIs for one year or longer or taking high doses of these drugs. The FDA encourages health care providers and consumers to report adverse events associated with these drugs to FDA's MedWatch Adverse Event Reporting Program or calling 1-800-332-1088.
"Because these products are used by a great number of people, it's important for the public to be aware of this possible increased risk and, when prescribing PPIs, health care professionals should consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition," Joyce Korvick, M.D., deputy director for safety in the FDA's Division of Gastroenterology Products, said in a statement.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top